Emactuzumab, a CSF1R inhibitor, improved patient-reported outcomes in a trial (NCT03193190) in diffuse-type tenosynovial giant cell tumors (dt-GCT) with durable responses (71% objective response rate) and fewer TAMs. Here, CSF1R is linked to tenosynovial giant cell tumor, diffuse type.